Aclaris Therapeutics (ACRS) Cash from Restructuring (2016)

Aclaris Therapeutics (ACRS) recorded quarterly Cash from Restructuring of $2.8 million in Q1 2016.

Aclaris Therapeutics (ACRS) Cash from Restructuring (2016) Analysis & Trends

Aclaris Therapeutics' Cash from Restructuring history runs 1 years deep, the most recent figure standing at $2.8 million for Q1 2016.

In Q1 2016, Cash from Restructuring changed N/A year-over-year to $2.8 million; the TTM figure through Dec 2016 stood at $2.8 million (changed N/A YoY), while the FY2016 annual figure was $2.8 million, changed N/A from the prior year.
Cash from Restructuring was $2.8 million for Q1 2016 at Aclaris Therapeutics.
In the past five years, Cash from Restructuring ranged from a high of $2.8 million in Q1 2016 to a low of $2.8 million in Q1 2016.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Aclaris Therapeutics	580.93 Mn	580.93 Mn	1.60 Mn

Historic Data

Download Data

Date	Value
Mar 31, 2016	2.78 Mn